Previous 10 | Next 10 |
Cabaletta Bio press release (NASDAQ:CABA): Q4 GAAP EPS of -$0.49 beats by $0.11. As of December 31, 2021, cash and cash equivalents and investments of $122.2 million, compared to $108.7 million as of December 31, 2020 For further details see: Cabaletta Bio GAAP EPS of -$0.49 beats by $0...
– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific meetings in mid-2022 – – MuSK-CAART Investigational ...
Investor Notice: April 29th Deadline in Lawsuit for Investors who Lost over $50,000 in Cabaletta Bio, Inc. shares announced by Shareholders Foundation PR Newswire SAN DIEGO , March 15, 2022 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that ...
Cabaletta Bio (NASDAQ:CABA) stock jumped 11% premarket after the U.S. FDA granted Fast Track Designation for MuSK-CAART, or muscle-specific kinase (MuSK) chimeric autoantibody receptor T (MuSK-CAART) cells, to improve muscle strength in patients with MuSK antibody-positive myasthenia gravis. ...
CTI BioPharma (NASDAQ:CTIC) +55% announces FDA accelerated approval of VONJ (pacritinib) for the treatment of adult patients with myelofibrosis and thrombocytopenia. American Rebel (NASDAQ:AREB) +24%. 3D Systems DDD +14% on Q4 results. Lilium N.V. (NASDAQ:LILM) +8%. Editas Medicine ...
– Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis – PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology co...
PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and ...
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the promotions of Gwendol...
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...